Both liraglutide and exenatide reduced blood glucose levels in a study involving more than 900 patients with type 2 diabetes, researchers report in The Lancet.
Patients getting daily injections of liraglutide lost slightly more weight but also had somewhat higher rates of side effects than those getting weekly exenatide injections. The primary difference between the two glucagon-like peptide-1 receptor agonists is the frequency and complexity of the injections, said endocrinologist Spyros Mezitis.

Full Story:
HealthDay News

Related Summaries